Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis, PMID: 33053283
Abatacept: A Review in Rheumatoid Arthritis, PMID: 28608166
Abatacept for the treatment of rheumatoid arthritis, PMID: 30730220
How does abatacept really work in rheumatoid arthritis?, PMID: 29401118
Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency, PMID: 31238161
[Abatacept], PMID: 27311187
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis, PMID: 31189043
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial, PMID: 31342624
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients, PMID: 33068439
Abatacept for the treatment of psoriatic arthritis, PMID: 30246575
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis, PMID: 33029724
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial, PMID: 28993346
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis, PMID: 29285605
Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study, PMID: 30535094
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients, PMID: 29422324
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis, PMID: 33406336
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study, PMID: 30679233
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study, PMID: 31703717
Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly, PMID: 29651639
Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders, PMID: 29737909
Abatacept in the treatment of localized scleroderma: A pediatric case series and systematic literature review, PMID: 32504991
A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis, PMID: 28133925
CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes, PMID: 32031422
The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation, PMID: 27135404
Abatacept, PMID: 19843049
Abatacept for the treatment of systemic lupus erythematosus, PMID: 26878310
Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials, PMID: 26692536
Efficacy of abatacept for Felty's syndrome, PMID: 31292638
Abatacept for rheumatoid arthritis: a Cochrane systematic review, PMID: 20080922
Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study, PMID: 31880308
Abatacept Monotherapy Versus Abatacept Plus Methotrexate for Treatment-Refractory Rheumatoid Arthritis, PMID: 29023282
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden, PMID: 28975211
Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production, PMID: 31994996
Practice guidelines for the use of subcutaneous abatacept, PMID: 24387951
Subcutaneous abatacept in rheumatoid arthritis: current update, PMID: 26160492
Abatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a blinded trial in mice, PMID: 31064410
Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists, PMID: 16971318
JAK1 inhibitor superior to abatacept in head-to-head RA trial, PMID: 33110224
Abatacept alleviates rheumatoid arthritis development by inhibiting migration of fibroblast-like synoviocytes via MAPK pathway, PMID: 31002160
Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis, PMID: 20099018
Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment, PMID: 28465078
Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register, PMID: 31969172
Does Abatacept Increase Postoperative Adverse Events in Rheumatoid Arthritis Compared with Conventional Synthetic Disease-modifying Drugs?, PMID: 31203226
Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis, PMID: 32998980
Successful abatacept treatment for Felty's syndrome in a patient with rheumatoid arthritis, PMID: 33086993
Abatacept Use Is Associated with Steroid Dose Reduction and Improvement in Fatigue and CD4-Dysregulation in CVID Patients with Interstitial Lung Disease, PMID: 33223097
Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature, PMID: 31027870
Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis, PMID: 32760165
Abatacept as a successful therapy for myositis—a case-based review, PMID: 24493331
Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries, PMID: 31300979
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial., PMID:40527572
CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting., PMID:40527414
A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe, granulomatosis with polyangiitis., PMID:40506793
Abatacept and multiple therapeutic bronchoscopies as salvage therapy for refractory tracheobronchial inflammation and stenosis in GPA., PMID:40506105
Optimal GVHD Prophylaxis., PMID:40488825
Allogeneic Transplantation for Older Adults., PMID:40488822
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders., PMID:40465294
Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417
Autoantibodies as prognostic markers in rheumatoid arthritis., PMID:40458132
Switching to IL-6 inhibitors or abatacept in elderly patients with rheumatoid arthritis achieving low disease activity with jak inhibitors: a pilot study., PMID:40455033
Multi-omics analysis of Helicobacter pylori-associated gastric cancer identifies hub genes as a novel therapeutic biomarker., PMID:40445003
FDA Approval Summary: Abatacept for prophylaxis of acute graft versus host disease., PMID:40435096
Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review., PMID:40431608
New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review., PMID:40430462
β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 Diabetes., PMID:40424079
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A report from the CIBMTR., PMID:40398621
Disseminated cat-scratch disease during abatacept therapy for rheumatoid arthritis in an older patient: A case report and review of the literature., PMID:40379021
Humoral immunogenicity after vaccination with the fourth dose of COVID-19 in patients with immunomediated inflammatory diseases., PMID:40378626
Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes., PMID:40374481
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis., PMID:40347194
The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid-Induced Fibrosis Mice., PMID:40344312
Abatacept-induced lupus erythematosus tumidus: A case report and literature review., PMID:40342196
Cost evaluation in head and neck cancer clinical trials: implications for high-value care., PMID:40339439
Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis., PMID:40335724
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland., PMID:40334913
Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation., PMID:40301664
SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial., PMID:40297751
Toxoplasma Gondii Replication During Belatacept Treatment in Kidney Transplantation: A Case Report and a Review of the Literature., PMID:40282351
Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial., PMID:40281208
Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study., PMID:40280051
Short Form-36 psychometric properties in idiopathic inflammatory myopathies: reliability, validity, and responsiveness., PMID:40279268
Real-World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020-2022., PMID:40276902
Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD)., PMID:40272902
Macrophage-Tased Dual-Phase T Cell Immunomodulation to Combat Transplant Rejection., PMID:40264278
Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritis., PMID:40259340
Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review., PMID:40256995
Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents., PMID:40249052
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction., PMID:40246381
Macrophage requirements for abatacept response in rheumatoid arthritis., PMID:40242906
Long-Term Outcomes of Belatacept Versus Tacrolimus Following T-Cell Depleting Induction in Adult Kidney Transplantation., PMID:40232892
Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database., PMID:40232336
Impact of csDMARDs vs. b/tsDMARDs on the Prognosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter, Retrospective Study., PMID:40218150
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors., PMID:40199607
Emerging therapeutics in the management of food allergy., PMID:40189990
Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis., PMID:40178703
Verification of unmet medical needs in patients with juvenile idiopathic arthritis in Japan., PMID:40160024
Successful treatment of rheumatoid arthritis complicated by anti-Jo-1 antibody-positive myopathy with abatacept: A case report., PMID:40159152
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment., PMID:40142915
For research use only. Not for human or drug use.
